A prominent participant in the global Contract Research, Development, and Manufacturing Services (CRAMS) market, Sai Life Sciences is preparing for its December 2024 IPO. By taking this action, the business will be able to raise money and give investors a chance to get involved in the rapidly expanding pharmaceutical services industry. The Sai Life Sciences IPO is receiving a lot of attention because of its solid market position and existing clientele.
Sai Life Sciences Overview
Sai Life Sciences specializes in offering pharmaceutical companies all over the world comprehensive services in drug development, manufacturing, and discovery. With a strong emphasis on lowering operating costs for its clients by providing top-notch outsourced services, the company operates globally. TPG Capital, which supports it, has contributed to the company’s growth by allowing it to enhance its technological and infrastructure capabilities.
From early research to commercial manufacturing, the company offers services that cover a number of stages of the drug development lifecycle. It has developed into a crucial ally for pharmaceutical firms seeking to optimize their workflows and lower the expenses related to drug manufacturing. This industry, called CRAMS, has been expanding quickly as pharmaceutical companies depend more and more on outside vendors for different parts of their business operations. Sai Life Sciences is well-positioned to profit from the ongoing expansion of the global CRAMS market thanks to its solid track record and wealth of experience in this area.
Sai Life Sciences IPO Specifics
The initial public offering (IPO) for Sai Life Sciences is scheduled to open on December 11, 2024, and close on December 13, 2024. The issue price per share is set between ₹522 and ₹549. The business is providing both a secondary sale by its current investors and a new issue of equity shares. It is anticipated that the offering will raise a total of ₹3042.62 crores, of which ₹950 crores will be attributable to the new issue.
By purchasing a minimum of 27 shares, or a minimum investment of ₹14,823, retail investors can take part in the IPO. On December 18, 2024, the shares are anticipated to be listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).
Market Position and Finances
In recent years, Sai Life Sciences has demonstrated remarkable financial growth. Over 97% of the company’s revenue comes from customers outside of India, making its international business a major source of income. A substantial amount of Sai Life Sciences’ ₹14,386 crore in revenue for the fiscal year that concluded on March 31, 2024, came from contract research and manufacturing activities.
Notwithstanding these remarkable figures, the business is exposed to a number of risks. For instance, it depends heavily on a small number of important clients, and the possible loss of these customers could have a negative impact on its revenue stream. Furthermore, the business works in a highly regulated and competitive sector where operational difficulties or regulatory changes could cause business disruptions.
Nonetheless, Sai Life Sciences has been able to sustain strong relationships with important clients in the pharmaceutical industry thanks to its solid reputation and dedication to quality and innovation. Its market position is further reinforced by the rising demand for pharmaceutical services that are outsourced. It is anticipated that the company will continue to grow as a result of its investments in R&D and market expansion.
IPO Risk and Things to Think About
The Sai Life Sciences IPO has risks, just like any other investment. Despite its growth, the pharmaceutical industry is impacted by a number of outside variables, such as modifications to regulations and changes in consumer demand. Additionally, the business is up against rivals in the CRAMS market, which might put pressure on profits or impede expansion.
Furthermore, the company’s global operations expose it to geopolitical tensions, foreign exchange risks, and changes in international regulations that could affect its operations. There are ethical issues with the company’s use of animals in some of its research procedures, which could harm its reputation.
Final Thoughts
Investors have a thrilling chance to take part in the expansion of a major force in the CRAMS sector with the Sai Life Sciences IPO. With a solid financial history, expanding clientele, and a positive outlook for the sector, the business is in a good position to benefit from the rising demand for pharmaceutical services that are outsourced. The company’s reliance on significant clients, market competition, and regulatory changes are some of the inherent risks that prospective investors should be aware of. Before taking part in the IPO, it is essential to determine one’s personal risk tolerance, just like with any other investment.
The IPO application process is simple for those who wish to apply, and online applications can be submitted via ASBA or UPI. Shares will be credited to demat accounts by December 17, 2024, the day of the final allocation.
If you are interested for more: “Growing Value: Sai Life Sciences IPO Set to Have Strong
“Godrej Consumer Products: Harnessing FMCG Trends for Unst